NCT05323981View on ClinicalTrials.gov

Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection

PHASE1CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

October 9, 2022

Study Completion Date

October 9, 2022

Conditions
Similarity of Pharmacokinetics and Safety
Interventions
DRUG

HS627(210mg/7ml)

Intravenous drip of 420mg HS627

DRUG

HS627(420mg/14ml)

Intravenous drip of 420mg HS627

DRUG

Perjeta

Intravenous drip of 420mg PERJETA

Trial Locations (1)

266000

The Affiliated Hospital of Qingdao University, Qingdao

Sponsors
All Listed Sponsors
lead

BioRay Pharmaceutical Co., Ltd.

INDUSTRY